Attention-Deficit/Hyperactivity Disorder
Mental Health
Attention-Deficit/Hyperactivity Disorder is treated with 4 medications in our database, including Atomoxetine Hydrochloride, Guanfacine Extended-Release, QuilliChew ER, METADATE CD. 4 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Eli Lilly, Takeda, Tris, Lannett. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Attention-Deficit/Hyperactivity Disorder treatment below.
What help exists for Attention-Deficit/Hyperactivity Disorder
6
drugs indexed
3
with copay cards
4
with patient assistance
0
open travel grants
Every item below links to the manufacturer's or charity's own portal. RxCopays does not take referral fees.
Drugs used to treat Attention-Deficit/Hyperactivity Disorder
6 totalStrattera
Atomoxetine hydrochloride · Eli Lilly
QuilliChew ER
methylphenidate hydrochloride · Tris
🎟💙Atomoxetine Hydrochloride
atomoxetine hydrochloride · Eli Lilly
METADATE CD
methylphenidate hydrochloride · Lannett
🎟💙Atomoxetine
Atomoxetine · Eli Lilly
💙Guanfacine Extended-Release
guanfacine · Takeda
🎟💙
🎟 = copay card · 💙 = patient assistance program
Prior authorization patterns for Attention-Deficit/Hyperactivity Disorder drugs
Aggregated from CMS SPUF + commercial PBM formularies. Specific rules vary by plan; confirm with your insurer.
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |
— Medicare Part D | — | — | — |